Hypoxia-Responsive Retinoid Liposomes for Tumor Microenvironment-Activated Differentiation and Metastasis Suppression
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Chunlin Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China. Hauptthemen laut MEDLINE: Liposomes, Tumor Microenvironment, Tretinoin, Cell Differentiation. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province, Henan Province Medical Science and Technology Research Project.
Abstract (Originalsprache)
Cancer stem-like cells (CSCs) are a key driving factor of tumor heterogeneity, metastasis, and chemoresistance. All-trans retinoic acid (ATRA) shows strong potential for inducing CSC differentiation and reducing stemness; however, its clinical translation is limited by the lack of effective targeting and favorable biodistribution under physiological conditions. Here, we report a hypoxia-responsive ATRA-phospholipid conjugate (RAPC) as a delivery and differentiation-priming strategy, enabling the fabrication of ATRA-loaded liposomes (ATRA@Lip) with high drug loading and microenvironment-activated release. RAPC was synthesized via a modular route incorporating an azobenzene-based hypoxia-cleavable linker between ATRA and a phosphatidylcholine analog. By coassembling RAPC with cholesterol and phospholipid, stable liposomes were obtained with a maximal ATRA loading of 17 wt % at 50 mol % RAPC content. Under normoxia, ATRA@Lip exhibited minimal leakage, whereas hypoxic conditions triggered rapid azo bond cleavage and accelerated ATRA release. Functionally, hypoxia-triggered ATRA@Lip promoted CSC differentiation and enhanced the chemosensitivity of breast cancer cells to albumin-bound paclitaxel (Nab-PTX) in vitro. Collectively, this hypoxia-responsive lipid-drug conjugate platform enables functional CSC priming and improved combination chemotherapy, offering a promising strategy for microenvironment-activated modulation of CSC-associated chemoresistance in metastatic breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China.
- Department of Gynecology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China.
ORCID-Profile: Yonglian Wang
Förderung
- Natural Science Foundation of Henan Province
- Henan Province Medical Science and Technology Research Project
Zitieren
APA
Li, C., Liu, D., Li, X., Zhu, D., Zhang, H., & Wang, Y. (2026). Hypoxia-Responsive Retinoid Liposomes for Tumor Microenvironment-Activated Differentiation and Metastasis Suppression. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01284
Vancouver
Li C, Liu D, Li X, Zhu D, Zhang H, Wang Y. Hypoxia-Responsive Retinoid Liposomes for Tumor Microenvironment-Activated Differentiation and Metastasis Suppression. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01284
BibTeX
@article{Li2026,
author = {Li, Chunlin and Liu, Di and Li, Xiaojie and Zhu, Deqi and Zhang, Hong and Wang, Yonglian},
title = {Hypoxia-Responsive Retinoid Liposomes for Tumor Microenvironment-Activated Differentiation and Metastasis Suppression},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01284}
}
EUVIMED